What was once a distant dream is becoming a reality
Each year, more than 350,000 women die from a disease that medicine already knows how to prevent. On November 17, 2025, the World Health Organization marked the first World Cervical Cancer Elimination Day — not as ceremony alone, but as acknowledgment of a genuine turning point, as nations from Pakistan to Rwanda mobilize vaccination, screening, and treatment at a scale that transforms what was once aspiration into measurable progress. The tools have long existed; what is shifting now is the collective will to deploy them equitably, and with it, the possibility that a preventable death might one day become a historical artifact.
- Cervical cancer kills over 350,000 women annually — almost all of those deaths preventable — and the burden falls heaviest on women in the world's most under-resourced communities.
- Pakistan launched the largest single HPV vaccination campaign ever conducted by any nation, reaching 9 million girls, while Ghana, Nigeria, Angola, Sierra Leone, and others rolled out major drives in 2025 alone.
- The WHO's 90-70-90 framework — vaccinate 90% of girls, screen 70% of women, treat 90% of precancerous cases — is now the operational blueprint governments are racing to meet, with Rwanda targeting full compliance by 2027.
- Political commitment is hardening into funding: Nigeria's First Lady pledged $700,000, China added HPV vaccine to its national immunization schedule, and Spain committed a three-year regional investment across Africa and the Eastern Mediterranean.
- The critical test ahead is sustainability — whether screening infrastructure can keep pace with vaccination gains, whether treatment capacity scales in time, and whether momentum survives the political and logistical pressures that have stalled past global health campaigns.
On November 17, 2025, the World Health Organization convened the first World Cervical Cancer Elimination Day — a date mandated by the World Health Assembly to serve as an annual focal point for a disease that kills more than 350,000 women each year, despite being almost entirely preventable. The occasion arrived not as symbolic gesture alone, but as the visible crest of genuine momentum building across Africa, Asia, and beyond.
The WHO's strategy is clear in its ambition: vaccinate 90 percent of girls against human papillomavirus, screen 70 percent of women, and treat 90 percent of those found with precancer or invasive disease — the 90-70-90 framework. Director-General Dr. Tedros Adhanom Ghebreyesus, reflecting on the years since his 2018 global call to action, noted that what once seemed a distant dream is becoming measurable reality. Gavi and its partners estimate 86 million girls reached with HPV vaccination by the end of 2025.
The scale of individual country campaigns underscores the shift. Pakistan conducted what officials describe as the largest single HPV vaccination campaign ever mounted, reaching over 9 million girls aged 9 to 14. Ghana targeted 2.4 million girls in a nationwide October campaign. Sierra Leone, Liberia, Angola, Nigeria, Cuba, Nepal, Tajikistan, and Tunisia all introduced or expanded HPV vaccination in their national schedules during 2025. Rwanda's Mission 2027 plan is expanding screening and treatment nationwide with the explicit goal of meeting elimination targets three years ahead of the global timeline.
Political will is translating into resources. Nigeria's First Lady committed $700,000 through the Renewed Hope Initiative. South Africa elevated the issue at the G20. China added HPV vaccine to its national immunization programme for all 13-year-old girls. Spain committed a three-year investment supporting elimination efforts across Africa and the Eastern Mediterranean. Indonesia hosted the Second Global Forum for Cervical Cancer Elimination, reaffirming its 2030 targets.
What makes this moment distinct is not the existence of the tools — those have been available for years — but the political, financial, and logistical machinery now engaging to deploy them at scale. The disease remains concentrated among women in low-resource settings, where sparse infrastructure and historical medical skepticism compound the challenge. Whether the gains of 2025 translate into lives saved in the years ahead will depend on whether countries can sustain campaigns, expand treatment capacity, and ensure that the progress announced in conference halls reaches the women who need it most.
On November 17, 2025, the World Health Organization marked the first official World Cervical Cancer Elimination Day—a date mandated by the World Health Assembly and meant to serve as an annual rallying point for a disease that kills more than 350,000 women every year despite being almost entirely preventable. The day arrived not as symbolic gesture alone, but as the visible crest of genuine momentum: countries across Africa, Asia, and beyond are launching vaccination campaigns, expanding screening services, and treating precancerous lesions at a scale that seemed distant just years ago.
The disease itself remains the fourth most common cancer among women globally, yet the tools to eliminate it exist. The WHO's strategy is straightforward in its ambition: vaccinate 90 percent of girls against human papillomavirus, screen 70 percent of women, and treat 90 percent of those found to have precancer or invasive disease. These targets, known as the 90-70-90 framework, form the backbone of what the organization calls its global elimination strategy. Dr. Tedros Adhanom Ghebreyesus, the WHO Director-General, reflected on the distance traveled since 2018, when he first issued a global call to action on cervical cancer. "What was once a distant dream is becoming a reality," he said, noting that more countries are scaling vaccination, improving screening infrastructure, and expanding treatment access.
The numbers backing this claim are substantial. Gavi, the Vaccine Alliance, and its partners estimate that they have reached 86 million girls with HPV vaccination by the end of 2025—a figure that will be officially verified through WHO and UNICEF coverage estimates in July 2026. This single statistic captures the scale of the shift underway. Pakistan alone conducted what officials describe as the largest single HPV vaccination campaign any country has ever mounted, reaching over 9 million girls aged 9 to 14. Ghana ran a nationwide campaign in October 2025 targeting girls aged 9 to 14, aiming to vaccinate 2.4 million. Sierra Leone and Liberia together launched campaigns reaching more than 1.5 million girls. Angola, Cuba, Nepal, Nigeria, Tajikistan, and Tunisia all introduced or expanded HPV vaccination in their national immunization schedules during 2025.
The momentum extends beyond vaccination. In Sierra Leone, health authorities are planning a mass screening campaign across all 16 districts, followed by a public awareness walk. Malaysia is leveraging survivors as advocates, organizing a week-long promotion of self-sampling HPV testing—a technological innovation that removes barriers to screening in settings where traditional clinic-based approaches face logistical or cultural obstacles. Rwanda, through its Accelerated Plan for Elimination called Mission 2027, is rapidly expanding nationwide screening and treatment services with the explicit goal of meeting the 90-70-90 targets by 2027, three years ahead of the global timeline.
Governments are backing these efforts with political will and resources. Nigeria's First Lady, Senator Oluremi Tinubu, committed $700,000 through the country's Renewed Hope Initiative, signaling that cervical cancer elimination has become a priority at the highest levels of government. South Africa placed the issue on the agenda of the G20, the group of the world's largest economies, and is finalizing a National Strategic Framework for Cervical Cancer Elimination. China added the HPV vaccine to its national immunization programme, scaling access to all 13-year-old girls. Spain, through its international development cooperation agency, committed to a three-year investment supporting the WHO Cervical Cancer Elimination Initiative across the African and Eastern Mediterranean regions.
Indonesia hosted the Second Global Forum for Cervical Cancer Elimination and reaffirmed its commitment to elimination by 2030 through what it calls bold national targets, a strong partnership ecosystem, and substantial investments in vaccination, screening, and treatment under its National Cervical Cancer Elimination Plan. The Western Pacific Region saw Unitaid and WHO expand their partnership to strengthen prevention and treatment programs, with a focus on equitable access to screening and treatment for precancerous conditions.
What makes this moment distinct is not that the tools exist—they have existed for years—but that the political, financial, and logistical machinery to deploy them at scale is finally engaging. The first World Cervical Cancer Elimination Day serves as both celebration of distance traveled and marker of work ahead. The disease remains concentrated among women in low-resource settings, where screening infrastructure is sparse and vaccination campaigns must overcome not only logistical challenges but sometimes skepticism rooted in historical medical injustices. The next phase will test whether countries can sustain these campaigns, whether treatment capacity can keep pace with screening expansion, and whether the gains announced in 2025 translate into lives saved in the years to come.
Notable Quotes
More and more countries are scaling up HPV vaccination, improving screening, and expanding treatment, bringing us closer to a future free of cervical cancer.— Dr. Tedros Adhanom Ghebreyesus, WHO Director-General
Nigeria committed $700,000 through the Renewed Hope Initiative to cervical cancer elimination efforts.— Senator Oluremi Tinubu, Nigeria's First Lady
The Hearth Conversation Another angle on the story
Why does cervical cancer still kill 350,000 women a year if we have the tools to prevent it?
The tools exist—the vaccine, screening tests, treatment protocols—but they're not evenly distributed. Most deaths happen in low-income countries where screening programs don't exist, where girls don't have access to vaccination, where treatment facilities are far away or nonexistent. It's not a failure of medicine. It's a failure of access.
So what changed? Why is momentum building now?
Political will converged with funding. Countries saw that elimination was actually possible, not just a nice idea. When Pakistan decided to vaccinate 9 million girls in one campaign, it sent a signal: this can be done at scale. Other countries watched and thought, we can do that too.
Pakistan's campaign sounds enormous. How do you vaccinate 9 million girls?
You need coordination across districts, trained health workers, cold chain logistics to keep vaccines viable, and community buy-in. It's not simple, but it's doable if you commit resources and political attention. Pakistan proved the infrastructure can handle it.
Rwanda is aiming to finish by 2027, three years early. Is that realistic?
Rwanda has a track record of executing ambitious health goals. They're calling it Mission 2027 and they're investing heavily in screening and treatment infrastructure, not just vaccination. If they maintain that pace and funding, yes, it's realistic. But it depends on sustained political commitment and money.
What's the hardest part—getting girls vaccinated, screening women, or treating precancer?
All three are hard in different ways. Vaccination requires reaching adolescents and overcoming hesitancy. Screening requires infrastructure and trained workers. Treatment requires facilities and specialists. The countries doing well are tackling all three simultaneously, not waiting to finish one before starting the next.
Why does Malaysia's approach with self-sampling matter?
Because it removes friction. Women can test themselves at home instead of traveling to a clinic, waiting, facing stigma. It's a small innovation that dramatically expands who can be screened. That's how you move from 70 percent coverage to higher.